Edwards Lifesciences (NYSE:EW) yesterday advised its investors against joining in an unsolicited “mini-tender offer” by TRC Capital Corporation, which is looking to purchase approximately 1 million shares of the company’s stock.
The Irvine, Calif.-based company said it does not endorse the offering and recommended that its stockholders “reject the offer” either by doing nothing in response or by withdrawing their shares from the offer.
“Edwards is not affiliated or associated in any way with TRC Capital, its mini-tender offer or the offer documentation. The Securities and Exchange Commission has cautioned investors about these offers,” the company wrote in a press release.
TRC Capital is offering a fixed $162.38 per share, which is significantly lower than the current market price of $170.13 as of 10:06 a.m. EDT
“Edwards urges stockholders to obtain current market quotations for their shares, review the conditions to the offer or consult with their broker or financial adviser before any decision regarding the offer is considered by our stockholders,” Edwards wrote in a prepared statement.
Last month, Edwards’ board of directors authorized an additional $1 billion for stock repurchases, according to an SEC filing.